il 33  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Name:
    IL 33 Protein Canine Recombinant
    Description:
    A DNA sequence encoding the mature form of canine IL33 O97863 Ser 110 Ser 263 was expressed with an initial Met at the N terminus
    Catalog Number:
    70005-DNAE
    Price:
    None
    Category:
    recombinant protein
    Host:
    E. coli
    Buy from Supplier


    Structured Review

    Sino Biological il 33
    <t>IL-33</t> activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    A DNA sequence encoding the mature form of canine IL33 O97863 Ser 110 Ser 263 was expressed with an initial Met at the N terminus
    https://www.bioz.com/result/il 33/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    il 33 - by Bioz Stars, 2021-06
    97/100 stars

    Images

    1) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    2) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    3) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    4) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    5) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    6) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    7) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    8) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    9) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    10) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    11) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    12) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    13) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    14) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    15) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    16) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    17) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    18) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    19) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    20) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    21) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    22) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    23) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    24) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    25) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    26) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    27) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    28) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    29) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    30) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    31) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    32) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    33) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    34) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    35) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    36) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    37) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    38) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    39) Product Images from "Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML"

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    Journal: Frontiers in Immunology

    doi: 10.3389/fimmu.2020.595053

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P
    Figure Legend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Techniques Used: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P
    Figure Legend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Techniques Used: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P
    Figure Legend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Techniques Used: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P
    Figure Legend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Techniques Used: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P
    Figure Legend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Techniques Used: Expressing, Enzyme-linked Immunosorbent Assay

    Related Articles

    Recombinant:

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin
    Article Snippet: For all cell stimulation experiments, 2×105 cells were seeded in each well of 24-well or 8×105 cells were seeded in each well of 6-well plates. .. When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells. .. After 24 hours treatment, cells were collected for RNA isolation or western blot.

    Expressing:

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: .. Next, to examine whether IL-33 could provoke enhanced IL-6 expression in primary AML samples, we treated BM and PB cells with IL-33 or in combination with anti-IL-33 antibody for 72 h in culture and determined IL-6 expression. .. We found that IL-6 secretion was elevated in response to IL-33, while antibody blockade of IL-33 abrogated the effect on increased IL-6 secretion mediated by IL-33 in both BM and PB ( ).

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: Additionally, IL-33 treatment led to significantly increased IL-6 mRNA expression as compared to untreated cells. .. Interestingly, cells treated with the combination of IL-33 with anti-IL-33 antibody showed a trend towards decreased IL-6 mRNA expression as compared to IL-33 treatment alone, although this difference was not statistically significant in either BM or PB ( ). .. Together, our data suggest that IL-33 might work with IL-6 in the local and systemic circulation to support the maintenance of leukemia cells.

    other:

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: Together, our data indicate that IL-33 promotes cell survival by stimulating p38 MAPK pathway in AML patient samples.

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: We found that IL-6 secretion was elevated in response to IL-33, while antibody blockade of IL-33 abrogated the effect on increased IL-6 secretion mediated by IL-33 in both BM and PB ( ).

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: IL-33 is a recently identified cytokine that belongs to the IL-1 cytokine family ( ).

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: Moreover, the combination of IL-33 and SB decreased the proportion of cells in S phase as observed with IL-33 alone.

    Cell Culture:

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: We found that IL-33 significantly increased the phosphorylation of both p38 MAPK and ATF2 as compared to the untreated cells, while SB significantly reduced IL-33-induced p38 MAPK and ATF2 phosphorylation ( ). .. To determine if IL-33 activates p38 MAPK pathway in AML patient samples, primary AML cells from BM and PB were cultured and treated with IL-33 alone or in combination with SB for 72 h. Phosphorylation of p38 MAPK and ATF2 were measured by Western blot. .. We found that IL-33 treatment stimulated the phosphorylation of both p38 MAPK and ATF2, whereas the addition of SB diminished the effect of IL-33-induced activation of p38 and ATF2 ( ).

    Western Blot:

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML
    Article Snippet: We found that IL-33 significantly increased the phosphorylation of both p38 MAPK and ATF2 as compared to the untreated cells, while SB significantly reduced IL-33-induced p38 MAPK and ATF2 phosphorylation ( ). .. To determine if IL-33 activates p38 MAPK pathway in AML patient samples, primary AML cells from BM and PB were cultured and treated with IL-33 alone or in combination with SB for 72 h. Phosphorylation of p38 MAPK and ATF2 were measured by Western blot. .. We found that IL-33 treatment stimulated the phosphorylation of both p38 MAPK and ATF2, whereas the addition of SB diminished the effect of IL-33-induced activation of p38 and ATF2 ( ).

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Sino Biological recombinant murine il 33
    Staphylococcus aureus activates MAPKs-AKT-STAT3 signaling to induce <t>IL-33.</t> ( A B ) Quantification of IL-33 mRNA of macrophages RAW264.7 treated with 10 µg/ml PGN ( A ) or LTA ( B ) in the presence or absence of different inhibitors. SB: p38 MAPK inhibitor SB202190 (5 µM); PD: MEK1 inhibitor PD98059 (20 µM); SP: JNK inhibitor SP600125 (15 µM); Ly: AKT inhibitor Ly294002 (50 µM); ST: STAT3 inhibitor S31-201 (50 µM). ( C ) Western blot of IL-33 in macrophages RAW264.7 stimulated by PGN in the presence or absence of inhibitors. * Unspecific bands. ( D ) Phosphorylation of p38 MAPK (Thr180/Tyr182), AKT (Ser473) and STAT3 (Tyr705) after RAW264.7 cells treated with 10 µg/ml PGN or LTA for 1–5 h. ( E ) Phosphorylation of JNK (Thr183/Tyr185) and ERK (Thr202/Tyr204) after RAW264.7 cells treated with 10 µg/ml PGN for 1–5 h. ( F ) Phosphorylation of p38 MAPK (Thr180/Tyr182) after wild-type and Tlr2 −/− primary peritoneal macrophages treated with 10 µg/ml PGN for 1–5 h. ( G ) Phosphorylation of p38 MAPK (Thr180/Tyr182) and AKT (Ser473) after macrophages RAW264.7 treated with 10 µg/ml PGN in the presence of p38MAPK inhibitor SB202190 or AKT inhibitor Ly294002. ( H ) Phosphorylation of AKT (Ser473) and STAT3 (Tyr705) after macrophages RAW264.7 treated with 10 µg/ml PGN in the presence of AKT inhibitor Ly294002 or STAT3 inhibitor S31-201. ***P
    Recombinant Murine Il 33, supplied by Sino Biological, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant murine il 33/product/Sino Biological
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant murine il 33 - by Bioz Stars, 2021-06
    97/100 stars
      Buy from Supplier

    N/A
    Produced in rabbits immunized with purified recombinant Human IL 33 rh IL 33 Catalog 10368 HNAE Ser 112 Thr 270 NP 254274 1 IL 33 specific IgG was purified by
      Buy from Supplier

    N/A
    A DNA sequence encoding the cynomolgus IL33 XP 005581824 1 Ser112 Ile270 was expressed with an initial Met
      Buy from Supplier

    N/A
    This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant Human IL 33 rh
      Buy from Supplier

    Image Search Results


    Staphylococcus aureus activates MAPKs-AKT-STAT3 signaling to induce IL-33. ( A B ) Quantification of IL-33 mRNA of macrophages RAW264.7 treated with 10 µg/ml PGN ( A ) or LTA ( B ) in the presence or absence of different inhibitors. SB: p38 MAPK inhibitor SB202190 (5 µM); PD: MEK1 inhibitor PD98059 (20 µM); SP: JNK inhibitor SP600125 (15 µM); Ly: AKT inhibitor Ly294002 (50 µM); ST: STAT3 inhibitor S31-201 (50 µM). ( C ) Western blot of IL-33 in macrophages RAW264.7 stimulated by PGN in the presence or absence of inhibitors. * Unspecific bands. ( D ) Phosphorylation of p38 MAPK (Thr180/Tyr182), AKT (Ser473) and STAT3 (Tyr705) after RAW264.7 cells treated with 10 µg/ml PGN or LTA for 1–5 h. ( E ) Phosphorylation of JNK (Thr183/Tyr185) and ERK (Thr202/Tyr204) after RAW264.7 cells treated with 10 µg/ml PGN for 1–5 h. ( F ) Phosphorylation of p38 MAPK (Thr180/Tyr182) after wild-type and Tlr2 −/− primary peritoneal macrophages treated with 10 µg/ml PGN for 1–5 h. ( G ) Phosphorylation of p38 MAPK (Thr180/Tyr182) and AKT (Ser473) after macrophages RAW264.7 treated with 10 µg/ml PGN in the presence of p38MAPK inhibitor SB202190 or AKT inhibitor Ly294002. ( H ) Phosphorylation of AKT (Ser473) and STAT3 (Tyr705) after macrophages RAW264.7 treated with 10 µg/ml PGN in the presence of AKT inhibitor Ly294002 or STAT3 inhibitor S31-201. ***P

    Journal: PLoS Pathogens

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin

    doi: 10.1371/journal.ppat.1003918

    Figure Lengend Snippet: Staphylococcus aureus activates MAPKs-AKT-STAT3 signaling to induce IL-33. ( A B ) Quantification of IL-33 mRNA of macrophages RAW264.7 treated with 10 µg/ml PGN ( A ) or LTA ( B ) in the presence or absence of different inhibitors. SB: p38 MAPK inhibitor SB202190 (5 µM); PD: MEK1 inhibitor PD98059 (20 µM); SP: JNK inhibitor SP600125 (15 µM); Ly: AKT inhibitor Ly294002 (50 µM); ST: STAT3 inhibitor S31-201 (50 µM). ( C ) Western blot of IL-33 in macrophages RAW264.7 stimulated by PGN in the presence or absence of inhibitors. * Unspecific bands. ( D ) Phosphorylation of p38 MAPK (Thr180/Tyr182), AKT (Ser473) and STAT3 (Tyr705) after RAW264.7 cells treated with 10 µg/ml PGN or LTA for 1–5 h. ( E ) Phosphorylation of JNK (Thr183/Tyr185) and ERK (Thr202/Tyr204) after RAW264.7 cells treated with 10 µg/ml PGN for 1–5 h. ( F ) Phosphorylation of p38 MAPK (Thr180/Tyr182) after wild-type and Tlr2 −/− primary peritoneal macrophages treated with 10 µg/ml PGN for 1–5 h. ( G ) Phosphorylation of p38 MAPK (Thr180/Tyr182) and AKT (Ser473) after macrophages RAW264.7 treated with 10 µg/ml PGN in the presence of p38MAPK inhibitor SB202190 or AKT inhibitor Ly294002. ( H ) Phosphorylation of AKT (Ser473) and STAT3 (Tyr705) after macrophages RAW264.7 treated with 10 µg/ml PGN in the presence of AKT inhibitor Ly294002 or STAT3 inhibitor S31-201. ***P

    Article Snippet: When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells.

    Techniques: Western Blot

    IL-33 expression in skin after Staphylococcus aureus infection. ( A ) Western blot of IL-33 in skin extracts from S.aureus -infected patients. Samples from 3 S.aureus -infected patients with abscess were pooled together. ( B ) Immunofluorescence analysis of IL-33 in skin of S.aureus -infected patients. This image is representative of three patients with abscess. Dotted white lines indicate the location of dermal-epidermal junction. Red scale bar represents 10 µm and white scale bars represent 50 µm. The arrow designates region of 200× magnification shown in inset. ( C ) Western blot of IL-33 in skin extracts from S.aureus -infected mice. Samples from 3 S.aureus -infected mice were pooled together. ( D ) Quantification of IL-33 expression in skin and the lesional size of skin lesions after mouse back skin infected with 1–2×10 7 CFU S.aureus . Normal skin without infection was collected as control. ( E ) Immunofluorescence analysis of IL-33 and F4/80 (macrophage marker) in mouse skin after S.aureus infection. This image is representative of six mice with abscess. Dotted white lines indicate the location of dermal-epidermal junction. Red scale bar represents 10 µm and white scale bar represents 50 µm. Arrows designate region of 200× magnification shown in insets. ( F ) IL-33 expression in RAW264.7 cells stimulated with different doses of heat-inactivated S.aureus for 24 hours. *P

    Journal: PLoS Pathogens

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin

    doi: 10.1371/journal.ppat.1003918

    Figure Lengend Snippet: IL-33 expression in skin after Staphylococcus aureus infection. ( A ) Western blot of IL-33 in skin extracts from S.aureus -infected patients. Samples from 3 S.aureus -infected patients with abscess were pooled together. ( B ) Immunofluorescence analysis of IL-33 in skin of S.aureus -infected patients. This image is representative of three patients with abscess. Dotted white lines indicate the location of dermal-epidermal junction. Red scale bar represents 10 µm and white scale bars represent 50 µm. The arrow designates region of 200× magnification shown in inset. ( C ) Western blot of IL-33 in skin extracts from S.aureus -infected mice. Samples from 3 S.aureus -infected mice were pooled together. ( D ) Quantification of IL-33 expression in skin and the lesional size of skin lesions after mouse back skin infected with 1–2×10 7 CFU S.aureus . Normal skin without infection was collected as control. ( E ) Immunofluorescence analysis of IL-33 and F4/80 (macrophage marker) in mouse skin after S.aureus infection. This image is representative of six mice with abscess. Dotted white lines indicate the location of dermal-epidermal junction. Red scale bar represents 10 µm and white scale bar represents 50 µm. Arrows designate region of 200× magnification shown in insets. ( F ) IL-33 expression in RAW264.7 cells stimulated with different doses of heat-inactivated S.aureus for 24 hours. *P

    Article Snippet: When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells.

    Techniques: Expressing, Infection, Western Blot, Immunofluorescence, Mouse Assay, Marker

    IL-33 induces iNOS in macrophages. ( A – C ) iNOS expression induced by heat-inactivated S.aureus ( A ) or PGN ( B ) or LTA( C ) before or after IL-33 was silenced in primary peritoneal macrophages. ( D ) Quantification of iNOS mRNA expression of WT and Tlr2 −/− primary peritoneal macrophages treated with 10 µg/ml PGN. ( E F ) iNOS mRNA expression in BMDMs treated with 30 ng/ml full-length IL-33( E ) or in primary peritoneal macrophages treated with 30 ng/ml processed IL-33(Ser109-Ile266) ( F ) for various times. ( G H ) Western blot of iNOS in BMDMs treated with 30 ng/ml full-length IL-33( G ) or in primary peritoneal macrophages treated with 30 ng/ml processed IL-33(Ser109-Ile266) ( H ) for various times. *P

    Journal: PLoS Pathogens

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin

    doi: 10.1371/journal.ppat.1003918

    Figure Lengend Snippet: IL-33 induces iNOS in macrophages. ( A – C ) iNOS expression induced by heat-inactivated S.aureus ( A ) or PGN ( B ) or LTA( C ) before or after IL-33 was silenced in primary peritoneal macrophages. ( D ) Quantification of iNOS mRNA expression of WT and Tlr2 −/− primary peritoneal macrophages treated with 10 µg/ml PGN. ( E F ) iNOS mRNA expression in BMDMs treated with 30 ng/ml full-length IL-33( E ) or in primary peritoneal macrophages treated with 30 ng/ml processed IL-33(Ser109-Ile266) ( F ) for various times. ( G H ) Western blot of iNOS in BMDMs treated with 30 ng/ml full-length IL-33( G ) or in primary peritoneal macrophages treated with 30 ng/ml processed IL-33(Ser109-Ile266) ( H ) for various times. *P

    Article Snippet: When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells.

    Techniques: Expressing, Western Blot

    IL-33 activates ST2-AKT-β-catenin to induce iNOS. ( A ) iNOS mRNA expression induced by 30 ng/ml processed IL-33(Ser109-Ile266) before or after ST2 was silenced in primary peritoneal macrophages. ( B ) Western blot of iNOS in WT, ST2 −/− and IL1R −/− primary peritoneal macrophages treated with 30 ng/ml processed IL-33(Ser109-Ile266) for different times. ( C ) iNOS mRNA expression induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of different inhibitors. SB: p38 MAPK inhibitor SB202190 (5 µM); PD: MEK1 inhibitor PD98059 (20 µM); SP: JNK inhibitor SP600125 (15 µM); Ly: AKT inhibitor Ly294002 (50 µM); ST: STAT3 inhibitor S3I-201 (50 µM). ( D ) iNOS mRNA expression induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT1/2 specific inhibitor (8 µM) or β-catenin inhibitor cardamonin (9 µM). ( E ) Phosphorylation of AKT (Ser473) induced by 30 ng/ml processed IL-33(Ser109-Ile266) before and after ST2 was silenced in primary peritoneal macrophages. ( F ) Phosphorylation of AKT (Ser473) induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT1/2 specific inhibitor (8 µM) in primary peritoneal macrophages. ( G ) Phosphorylation of AKT (Ser473) and β-catenin (Ser675) induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT1/2 specific inhibitor (8 µM) or β-catenin inhibitor cardamonin (9 µM) in BMDMs. The phosphorylation of β-catenin at Ser675 resulted in the accumulation of total β-catenin in cells. **P

    Journal: PLoS Pathogens

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin

    doi: 10.1371/journal.ppat.1003918

    Figure Lengend Snippet: IL-33 activates ST2-AKT-β-catenin to induce iNOS. ( A ) iNOS mRNA expression induced by 30 ng/ml processed IL-33(Ser109-Ile266) before or after ST2 was silenced in primary peritoneal macrophages. ( B ) Western blot of iNOS in WT, ST2 −/− and IL1R −/− primary peritoneal macrophages treated with 30 ng/ml processed IL-33(Ser109-Ile266) for different times. ( C ) iNOS mRNA expression induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of different inhibitors. SB: p38 MAPK inhibitor SB202190 (5 µM); PD: MEK1 inhibitor PD98059 (20 µM); SP: JNK inhibitor SP600125 (15 µM); Ly: AKT inhibitor Ly294002 (50 µM); ST: STAT3 inhibitor S3I-201 (50 µM). ( D ) iNOS mRNA expression induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT1/2 specific inhibitor (8 µM) or β-catenin inhibitor cardamonin (9 µM). ( E ) Phosphorylation of AKT (Ser473) induced by 30 ng/ml processed IL-33(Ser109-Ile266) before and after ST2 was silenced in primary peritoneal macrophages. ( F ) Phosphorylation of AKT (Ser473) induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT1/2 specific inhibitor (8 µM) in primary peritoneal macrophages. ( G ) Phosphorylation of AKT (Ser473) and β-catenin (Ser675) induced by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT1/2 specific inhibitor (8 µM) or β-catenin inhibitor cardamonin (9 µM) in BMDMs. The phosphorylation of β-catenin at Ser675 resulted in the accumulation of total β-catenin in cells. **P

    Article Snippet: When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells.

    Techniques: Expressing, Western Blot

    IL-33 activates iNOS to release NO against Staphylococcus aureus infection. ( A ) Acidified nitrite inhibited S.aureus growth in vitro . ( B ) Different doses of processed IL-33(Ser109-Ile266) induced NO release in RAW264.7 cells. ( C ) The release of NO by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of iNOS inhibitor aminoguanidine. ( D ) The survival of S.aureus in the intracellular of RAW264.7 cells after stimulated with 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of aminoguanidine. ( E ) The release of NO by heat-inactivated S.aureus after IL-33 was silenced. ( F ) The survival of S.aureus in RAW264.7 cells stimulated by 30 ng/ml processed IL-33(Ser109-Ile266) before and after IL-33 was silenced. ( G ) The survival of S.aureus in RAW264.7 cells after treated with 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT inhibitor Ly294002 (50 µM). ( H ) Western blot of iNOS in skin lesions caused by S.aureus infection at days 3 with or without IL-33 blockade. ( I ) Image J analysis of the lesion size of skin lesions treated as in ( H ). ( J ) Local S.aureus survival in skin lesions treated as in ( H ). ( K ) Gram-positive staining of S.aureus in infected skin of ( H ). ( L ) Local S.aureus survival in skin of mice treated with NO-donor NONOate or iNOS inhibitor aminoguanidine. *P

    Journal: PLoS Pathogens

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin

    doi: 10.1371/journal.ppat.1003918

    Figure Lengend Snippet: IL-33 activates iNOS to release NO against Staphylococcus aureus infection. ( A ) Acidified nitrite inhibited S.aureus growth in vitro . ( B ) Different doses of processed IL-33(Ser109-Ile266) induced NO release in RAW264.7 cells. ( C ) The release of NO by 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of iNOS inhibitor aminoguanidine. ( D ) The survival of S.aureus in the intracellular of RAW264.7 cells after stimulated with 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of aminoguanidine. ( E ) The release of NO by heat-inactivated S.aureus after IL-33 was silenced. ( F ) The survival of S.aureus in RAW264.7 cells stimulated by 30 ng/ml processed IL-33(Ser109-Ile266) before and after IL-33 was silenced. ( G ) The survival of S.aureus in RAW264.7 cells after treated with 30 ng/ml processed IL-33(Ser109-Ile266) in the presence or absence of AKT inhibitor Ly294002 (50 µM). ( H ) Western blot of iNOS in skin lesions caused by S.aureus infection at days 3 with or without IL-33 blockade. ( I ) Image J analysis of the lesion size of skin lesions treated as in ( H ). ( J ) Local S.aureus survival in skin lesions treated as in ( H ). ( K ) Gram-positive staining of S.aureus in infected skin of ( H ). ( L ) Local S.aureus survival in skin of mice treated with NO-donor NONOate or iNOS inhibitor aminoguanidine. *P

    Article Snippet: When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells.

    Techniques: Infection, In Vitro, Western Blot, Staining, Mouse Assay

    TLR2 is required for Staphylococcus aureus to induce IL-33. ( A ) Gram-positive staining of mouse skin infected with S.aureus . Scale bar represents 50 µm. ( B ) Local S.aureus survival in skin lesions at day-3 post-infection. (C) Immunofluorescent staining of IL-33 in wild-type and Tlr2 −/− mouse skin infected with S.aureus . This image is representative of six mice with abscess. Scale bar represents 50 µm. ( D ) Western blot of IL-33 in skin lesions caused by S.aureus infection at 3 days. 1, 2, 3 represent three mice of each group were used. ( E ) Quantification of IL-33 mRNA expression in skin of wild-type and Tlr2 −/− mice infected with S.aureus . ( F ) IL-33 mRNA expression in primary peritoneal macrophages from wild-type and Tlr2 −/− mice stimulated with 10 µg/ml PGN. ( G ) Western blot of IL-33 in primary peritoneal macrophages from wild-type and Tlr2 −/− mice stimulated with 10 µg/ml PGN for different times. **P

    Journal: PLoS Pathogens

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin

    doi: 10.1371/journal.ppat.1003918

    Figure Lengend Snippet: TLR2 is required for Staphylococcus aureus to induce IL-33. ( A ) Gram-positive staining of mouse skin infected with S.aureus . Scale bar represents 50 µm. ( B ) Local S.aureus survival in skin lesions at day-3 post-infection. (C) Immunofluorescent staining of IL-33 in wild-type and Tlr2 −/− mouse skin infected with S.aureus . This image is representative of six mice with abscess. Scale bar represents 50 µm. ( D ) Western blot of IL-33 in skin lesions caused by S.aureus infection at 3 days. 1, 2, 3 represent three mice of each group were used. ( E ) Quantification of IL-33 mRNA expression in skin of wild-type and Tlr2 −/− mice infected with S.aureus . ( F ) IL-33 mRNA expression in primary peritoneal macrophages from wild-type and Tlr2 −/− mice stimulated with 10 µg/ml PGN. ( G ) Western blot of IL-33 in primary peritoneal macrophages from wild-type and Tlr2 −/− mice stimulated with 10 µg/ml PGN for different times. **P

    Article Snippet: When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells.

    Techniques: Staining, Infection, Mouse Assay, Western Blot, Expressing

    IL-33 expression induced by S.aureus -derived PGN and LTA in macrophages. ( A B ) Quantification of IL-33 expression in macrophages RAW264.7 treated with different doses of PGN ( A ) or treated with 10 µg/ml PGN for different times ( B ). ( C D ) Quantification of IL-33 expression in macrophages RAW264.7 treated with different doses of LTA ( C ) or treated with 10 µg/ml LTA for different times ( D ). ( E ) Western blot of IL-33 induced by commercial PGN (cPGN) and PGN purified from S.aureus CMCC(B)26003 (pPGN) in total cell lysate of primary peritoneal macrophages. ( F ) Western blot of IL-33 induced by PGN in total cell lysate of primary peritoneal macrophages at different time points. ( G ) Western blot of IL-33 from the cytoplasm or nucleus of macrophages RAW264.7 treated with 10 µg/ml PGN. Histone was used as an endogenous control for nuclear proteins and tubulin was used as an endogenous control for cytoplasmic proteins. ( H ) Immunofluorescent staining of IL-33 in macrophages RAW264.7 treated with PGN for 24 hours. Scale bar represents 50 µm. ( I ) IL-33 in cell culture media. Cell culture media of macrophages RAW264.7 treated with 10 µg/ml PGN was incubated with protein G beads coupled with IL-33 antibody for overnight. Next day, IL-33 captured by IL-33 antibody was eluted from beads for western blot. * P

    Journal: PLoS Pathogens

    Article Title: Interleukin-33 Increases Antibacterial Defense by Activation of Inducible Nitric Oxide Synthase in Skin

    doi: 10.1371/journal.ppat.1003918

    Figure Lengend Snippet: IL-33 expression induced by S.aureus -derived PGN and LTA in macrophages. ( A B ) Quantification of IL-33 expression in macrophages RAW264.7 treated with different doses of PGN ( A ) or treated with 10 µg/ml PGN for different times ( B ). ( C D ) Quantification of IL-33 expression in macrophages RAW264.7 treated with different doses of LTA ( C ) or treated with 10 µg/ml LTA for different times ( D ). ( E ) Western blot of IL-33 induced by commercial PGN (cPGN) and PGN purified from S.aureus CMCC(B)26003 (pPGN) in total cell lysate of primary peritoneal macrophages. ( F ) Western blot of IL-33 induced by PGN in total cell lysate of primary peritoneal macrophages at different time points. ( G ) Western blot of IL-33 from the cytoplasm or nucleus of macrophages RAW264.7 treated with 10 µg/ml PGN. Histone was used as an endogenous control for nuclear proteins and tubulin was used as an endogenous control for cytoplasmic proteins. ( H ) Immunofluorescent staining of IL-33 in macrophages RAW264.7 treated with PGN for 24 hours. Scale bar represents 50 µm. ( I ) IL-33 in cell culture media. Cell culture media of macrophages RAW264.7 treated with 10 µg/ml PGN was incubated with protein G beads coupled with IL-33 antibody for overnight. Next day, IL-33 captured by IL-33 antibody was eluted from beads for western blot. * P

    Article Snippet: When cells were grown to 80% confluence, the indicated doses of heat-inactivated S.aureus, PGN (Sigma), LTA (InvivoGen), recombinant murine IL-33 (R & D) or human IL-33 (Sino Biological Inc) or different inhibitors under concentrations without cytotoxicity or low cytotoxicity ( ) were used to stimulate cells.

    Techniques: Expressing, Derivative Assay, Western Blot, Purification, Staining, Cell Culture, Incubation

    IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Journal: Frontiers in Immunology

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    doi: 10.3389/fimmu.2020.595053

    Figure Lengend Snippet: IL-33 activates p38 MAPK pathway in primary AML samples. (A, B) The AML cell line HL-60 were treated with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graph shows the quantification of p-p38 and pATF2 protein in all groups. (C–F) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or in combination with SB (20 µM). P-p38, p38, pATF2, or GAPDH protein expression was probed by Western blot analysis. The bar graphs show the quantification of p-p38 and pATF2 protein in all groups. n≥3 ; * P

    Article Snippet: Next, to examine whether IL-33 could provoke enhanced IL-6 expression in primary AML samples, we treated BM and PB cells with IL-33 or in combination with anti-IL-33 antibody for 72 h in culture and determined IL-6 expression.

    Techniques: Expressing, Western Blot, Incubation

    IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Journal: Frontiers in Immunology

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    doi: 10.3389/fimmu.2020.595053

    Figure Lengend Snippet: IL-33 induces IL-6 expression and secretion in primary AML cells. (A) The relationship between IL-33 and IL-6. Spearman rank correlation analysis was performed to evaluate the correlation of serum IL-33 with IL-6 in patients with AML at diagnosis (n = 10). (B) PBMCs and BMMCs from patients diagnosed with AML were incubated for 72 h with IL-33 (100 ng/ml) or combined with anti-IL-33 (100 ng/ml). CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. (C, D) RNA/cDNA expression of cells from (B) was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. A significant difference in the mean IL-6 mRNA expression between compared with untreated cells was found in both BM and PB samples. n≥3; * P

    Article Snippet: Next, to examine whether IL-33 could provoke enhanced IL-6 expression in primary AML samples, we treated BM and PB cells with IL-33 or in combination with anti-IL-33 antibody for 72 h in culture and determined IL-6 expression.

    Techniques: Expressing, Incubation, Crocin Bleaching Assay, Real-time Polymerase Chain Reaction

    p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Journal: Frontiers in Immunology

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    doi: 10.3389/fimmu.2020.595053

    Figure Lengend Snippet: p38 MAPK pathway participates in IL-33-stimulated IL-6 expression and release. BMMCs from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h. (A) RNA/cDNA expression of cells was analyzed using quantitative real-time PCR using Actb as a reference control. Data are plotted as relative gene expression compared with the untreated control. (B) CBA was used to simultaneously measure IL-6 in supernatants from cell cultures, and plotted as fold change compared with untreated samples. n≥3; *P

    Article Snippet: Next, to examine whether IL-33 could provoke enhanced IL-6 expression in primary AML samples, we treated BM and PB cells with IL-33 or in combination with anti-IL-33 antibody for 72 h in culture and determined IL-6 expression.

    Techniques: Expressing, Cell Culture, Real-time Polymerase Chain Reaction, Crocin Bleaching Assay

    IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Journal: Frontiers in Immunology

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    doi: 10.3389/fimmu.2020.595053

    Figure Lengend Snippet: IL-33 promotes cell survival via p38 MAPK pathway in primary AML samples. BMMCs (A, B) and PBMCs (C, D) from pediatric patients with AML were cultured with IL-33 (100 ng/ml), or SB (20 µM) alone, or in combination for 72 h, and apoptosis was measured by Annexin V staining. Bar graphs show the relative Annexin V staining of leukemia cells as compared to the untreated cells. (E) BMMCs from AML patients were analyzed for cell cycle status. Bar graph shows the relative percentage of leukemia cells in the indicated phase of the cell cycle after culture for 72 h in the presence of IL-33 (100 ng/ml), SB (20 µM) or in combination, compared to the untreated cells. n≥3 ; * P

    Article Snippet: Next, to examine whether IL-33 could provoke enhanced IL-6 expression in primary AML samples, we treated BM and PB cells with IL-33 or in combination with anti-IL-33 antibody for 72 h in culture and determined IL-6 expression.

    Techniques: Cell Culture, Staining

    AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Journal: Frontiers in Immunology

    Article Title: Interleukin-33 Promotes Cell Survival via p38 MAPK-Mediated Interleukin-6 Gene Expression and Release in Pediatric AML

    doi: 10.3389/fimmu.2020.595053

    Figure Lengend Snippet: AML patients at diagnosis have elevated IL1RL1 expression and IL-33 level in the serum. (A, B) IL1RL1 expression is increased on the cell surface of BM cells from AML cohorts. BMMCs from patients with AML and healthy donors were analyzed for IL1RL1 expression. Each symbol represents one healthy donor or patient with AML. (C) ELISA assay was used to measure IL-33 levels in serum from AML patients at diagnosis and normal children. Each symbol represents one healthy donor or patient with AML. n ≥ 3; * P

    Article Snippet: Next, to examine whether IL-33 could provoke enhanced IL-6 expression in primary AML samples, we treated BM and PB cells with IL-33 or in combination with anti-IL-33 antibody for 72 h in culture and determined IL-6 expression.

    Techniques: Expressing, Enzyme-linked Immunosorbent Assay